Sri Lanka, April 28 -- The National Medicines Regulatory Authority (NMRA) stated that the falling value of the Rupee will require a review of maximum price limits for specific drugs.

NMRA Chairperson Dr Ananda Wijewickrama explained that because 85% of medicines are imported, the currency devaluation impacts costs even for supplies brought in from regional partners like India, Pakistan, and Bangladesh. While 60 medicines currently have price ceilings, the authority noted that not every drug will be affected, though a price increase is inevitable for some.

Regarding recent concerns over import license delays causing supply issues, Dr Wijewickrama clarified:

"There is no connection between that process and pricing, and those delays are n...